1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia

Technology appraisal guidance [TA29] Published date: 26 September 2001

  • Guidance
  • Tools and resources
  • Information for the public
  • History
  • Overview
  • 1 Guidance
  • 2 Clinical Need and Practice
  • 3 The Technology
  • 4 Evidence
  • 5 Implications for the NHS
  • 6 Implementation
  • 7 Further Research
  • 8 Review of guidance
  • Appendix A. Appraisal Committee Members
  • Appendix B. Sources of Evidence
  • Appendix C. Guidance on the use of fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia
  • Appendix D. Staging Systems
  • Changes after publication
  • About this guidance
  • Share
    • Share
    • Linked In
    • Twitter
    • Facebook
    • Email
    • More...
  • Download

Guidance

  • Next

Appendix C. Guidance on the use of fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia

Appendix C. Guidance on the use of fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia

'Understanding NICE Guidance', a summary of this guidance for patients and carers can be found on our website.


  • Next